Novanta NOVT Medical Solutions — Restructuring And Related Cost Incurred Cost
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novanta in its filing.
Tagged under the XBRL concept us-gaap:RestructuringAndRelatedCostIncurredCost.
The official record: Novanta’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novanta's medical solutions — restructuring and related cost incurred cost.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novanta's medical solutions — restructuring and related cost incurred cost?
- Novanta (NOVT) reported medical solutions — restructuring and related cost incurred cost of $2.76M in Q4 2025.
- How has Novanta's medical solutions — restructuring and related cost incurred cost changed year-over-year?
- Novanta's medical solutions — restructuring and related cost incurred cost increased by 63.2% year-over-year, from $1.69M to $2.76M.
- What is the long-term trend for Novanta's medical solutions — restructuring and related cost incurred cost?
- Over 2 years (2023 to 2025), Novanta's medical solutions — restructuring and related cost incurred cost has grown at a 116.3% compound annual growth rate (CAGR), from $2.36M to $11.05M.
- What does medical solutions — restructuring and related cost incurred cost mean?
- This captures the actual cash or accrued costs incurred during the execution of restructuring initiatives, such as severance, lease terminations, or asset write-downs. It provides transparency into the financial impact of strategic changes within the segment. Investors monitor this to evaluate the cost-effectiveness and progress of management's operational improvement plans.